Innate Pharma SA
IPHYF
|
$2.65
104.6%
300
|
Health Technology
(0.0% 1d) (10.6% 1m) (-10.2% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-62.5% volume)
Earnings Calendar:
Market Cap: $ 204,779,375
http://www.innate-pharma.com/en
Sec Filling | Patents | n/a employees
(FR) Innate Pharma SA is a biopharmaceutical company. It focuses on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. Its products include immunotherapy drugs and monoclonal antibodies. The Immunotherapy drugs are designated for cancer and inflammatory diseases. The Monoclonal antibodies targets receptors and pathways controlling the activation of innate immunity cells. The company was founded by Hervé Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié and François Romagné on September 15, 1999 and is headquartered in Marseille, France.
cancer immunotherapy antibody t-cell treatment ceiling cancer treatments
add to watch list Paper trade email alert is off
Press-releases
Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate
Published: 2024-04-10 (Crawled : 09:00) - biospace.com/
SNYNF | News | $92.7 0.63% 0
|
Health Technology
|
| O: -0.01%
H: 0.0%
C: 0.0%
SNY | News | $45.55 -1.21% 250K
|
Health Technology
|
| O: -0.32%
H: 0.0%
C: 0.0%
IPHA | $2.41 11K
|
Health Technology
|
| O: -3.85%
H: 1.2%
C: 0.8%
iph45 pharma drug candidate antibody preclinical
Innate Pharma Announces Its Participation in Upcoming April 2024 Investor Conference
Published: 2024-04-09 (Crawled : 09:00) - biospace.com/
SNYNF | News | $92.7 0.63% 0
|
Health Technology
|
| O: 0.28%
H: 0.0%
C: 0.0%
SNY | News | $45.55 -1.21% 250K
|
Health Technology
|
| O: -0.38%
H: 0.95%
C: 0.83%
IPHA | $2.41 11K
|
Health Technology
|
| O: 2.57%
H: 1.81%
C: 1.81%
pharma conference
Innate Pharma Files Its 2023 Universal Registration Document (Document d’enregistrement Universel) and 2023 Annual Report on Form 20-F
Published: 2024-04-05 (Crawled : 11:00) - biospace.com/
SNYNF | News | $92.7 0.63% 0
|
Health Technology
|
| O: -1.77%
H: 0.0%
C: -1.81%
SNY | News | $45.55 -1.21% 250K
|
Health Technology
|
| O: -3.44%
H: 0.0%
C: 0.0%
IPHA | $2.41 11K
|
Health Technology
|
| O: -0.4%
H: 0.0%
C: -5.22%
pharma report universal
Innate Pharma Reports Full Year 2023 Financial Results and Business Update
Published: 2024-03-21 (Crawled : 09:00) - biospace.com/
SNYNF | News | $92.7 0.63% 0
|
Health Technology
|
| O: 0.14%
H: 0.24%
C: 0.24%
SNY | News | $45.55 -1.21% 250K
|
Health Technology
|
| O: 0.3%
H: 0.0%
C: 0.0%
IPHA | $2.41 11K
|
Health Technology
|
| O: -4.51%
H: 4.25%
C: 0.96%
pharma business year update financial results
Innate Pharma Announces Its Participation to Upcoming Investor Conference - March 19, 2024
Published: 2024-03-19 (Crawled : 08:00) - biospace.com/
SNYNF | News | $92.7 0.63% 0
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: 0.0%
SNY | News | $45.55 -1.21% 250K
|
Health Technology
|
| O: -1.51%
H: 0.0%
C: 0.0%
IPHA | $2.41 11K
|
Health Technology
|
| O: 0.84%
H: 4.56%
C: 0.83%
pharma conference
Innate Pharma Announces Conference Call and Webcast for Full Year 2023 Financial Results
Published: 2024-03-14 (Crawled : 09:00) - biospace.com/
SNY | News | $45.55 -1.21% 250K
|
Health Technology
|
| O: 0.23%
H: 0.0%
C: 0.0%
IPHA | $2.41 11K
|
Health Technology
|
| O: -2.4%
H: 3.69%
C: 3.28%
pharma conference year financial results
Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin’s Lymphoma
Published: 2024-03-06 (Crawled : 12:00) - biospace.com/
SNYNF | News | $92.7 0.63% 0
|
Health Technology
|
| O: 0.0%
H: 0.8%
C: 0.8%
SNY | News | $45.55 -1.21% 250K
|
Health Technology
|
| O: -0.45%
H: 0.0%
C: 0.0%
IPHA | $2.41 11K
|
Health Technology
|
| O: 0.78%
H: 1.93%
C: 0.97%
iph6501 first study
Innate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024
Published: 2024-03-06 (Crawled : 11:00) - biospace.com/
SNYNF | News | $92.7 0.63% 0
|
Health Technology
|
| O: 0.0%
H: 0.8%
C: 0.8%
SNY | News | $45.55 -1.21% 250K
|
Health Technology
|
| O: -0.45%
H: 0.0%
C: 0.0%
IPHA | $2.41 11K
|
Health Technology
|
| O: 0.78%
H: 1.93%
C: 0.97%
iph45 pharma drug antibody preclinical
Innate Pharma Announces Its Participation to Upcoming March 2024 Investor Conference
Published: 2024-02-21 (Crawled : 07:00) - biospace.com/
SNYNF | News | $92.7 0.63% 0
|
Health Technology
|
| O: 1.7%
H: 0.0%
C: 0.0%
SNY | News | $45.55 -1.21% 250K
|
Health Technology
|
| O: -0.57%
H: 0.0%
C: 0.0%
IPHA | $2.41 11K
|
Health Technology
|
| O: -2.32%
H: 0.0%
C: 0.0%
pharma conference
Number of Shares and Voting Rights of Innate Pharma as of January 1, 2024
Published: 2024-01-12 (Crawled : 11:00) - biospace.com/
SNYNF | News | $92.7 0.63% 0
|
Health Technology
|
| O: 0.71%
H: 0.0%
C: 0.0%
SNY | News | $45.55 -1.21% 250K
|
Health Technology
|
| O: 0.06%
H: 0.0%
C: 0.0%
IPHA | $2.41 11K
|
Health Technology
|
| O: 0.0%
H: 0.36%
C: 0.36%
pharma
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 79% | 21% |
Top 10 Gainers
TIRX | $1.13 133.09% 44M
|
AGBA | $0.8978 124.45% 60M
|
Finance
BPTH | $6.18 90.74% 39M
|
Health Technology
INVO | $1.44 89.47% 3M
|
Health Technology
XPON | $2.66 37.82% 5.2M
|
SINT | $0.0504 35.12% 300M
|
Health Technology
THCH | $1.38 32.69% 9.9M
|
n/a
ALRN | $5.605 31.88% 210K
|
Health Technology
HOLO | $2.92 30.36% 22M
|
VTNR S | $1.25 27.66% 3.2M
|
Industrial Services
Last 48 Hours Insiders Buying
RELL | $10.21 3.55% 23K
|
Electronic Technology
|
13:30
IZEA | $2.53 15K
|
Technology Services
|
00:00
RKT P 383 | $11.74 3.16% 280K
|
Finance
|
22:30
CTRN P 18090 | $22.805 1.94% 12K
|
Retail Trade
|
22:00
BRN P 10650 | $2.8 0.36% 41K
|
Energy Minerals
|
21:00
NEOG P 10000 | $12.115 -0.21% 590K
|
Health Technology
|
16:30
RMCF | $3.53 1.7K
|
Consumer Non-Durables
|
20:10